During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting inventory of Zepbound and Mounjaro ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... injectable obesity drug Zepbound and diabetes medicine ...

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year over year to $3.1 billion. Sales for Zepbound, which ...

AP Health Writer (AP) — Eli Lilly is dialing back its 2024 forecast after ... Company shares tumbled after markets opened.

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...

We recently compiled a list of the 10 Best S&P 500 Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently published a list of 10 Stocks To Buy Before They Split Next. In this article, we are going to take a look at ...

Shares of Eli Lilly (NYSE ... full-year non-GAAP EPS of $16.10 to $16.60. What's behind Lilly's disappointing Q3 update? Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained ...